dr. mckay on fda approval of nivolumab/ipilimumab in frontline rcc
Published 6 years ago • 193 plays • Length 0:52Download video MP4
Download video MP3
Similar videos
-
1:34
fda approval of frontline nivolumab/ipilimumab combo in rcc
-
0:29
dr. mckay on fda approval of frontline cabozantinib in rcc
-
0:39
dr. lopes on the fda approval of nivolumab/ipilimumab in nsclc
-
6:01
metastatic rcc: using frontline ipilimumab/nivolumab
-
0:43
dr. eng on the fda approval of nivolumab plus ipilimumab in crc
-
1:34
fda approves frontline nivolumab for advanced melanoma
-
0:51
dr. pal on the frontline approval of nivolumab and ipilimumab in mrcc
-
1:24
dr. mcdermott on nivolumab plus ipilimumab in rcc
-
1:01
rana mckay, md, discusses checkmate214 investigating nivolumab ipilimumab in 1st line rcc patients
-
0:46
fda approval of second-dosing schedule of nivolumab
-
8:26
front-line therapy with nivolumab and salvage nivolumab ipilimumab in patients with advanced rcc
-
1:08
dr. motzer on nivolumab/ipilimumab activity in rcc
-
5:10
checkmate 214: patterns of progression with nivolumab plus ipilimumab versus sunitinib for rcc
-
1:40
dr. powles on fda approval of pembrolizumab plus axitinib in advanced rcc
-
4:50
ipilimumab/nivolumab in first-line mrcc
-
7:03
ipilimumab/nivolumab for favorable-risk mrcc
-
5:19
i-o therapy in mcrc: ipilimumab nivolumab
-
0:37
dr. petrylak on fda approval of nivolumab in bladder cancer
-
1:33
dr. mcdermott on single-agent nivolumab in rcc